Nyxoah SA - Ordinary Shares (NYXH)
6.9900
+0.4900 (7.54%)
NASDAQ · Last Trade: Apr 4th, 3:17 AM EDT
Detailed Quote
Previous Close | 6.500 |
---|---|
Open | 6.680 |
Bid | 5.550 |
Ask | 7.700 |
Day's Range | 6.450 - 7.351 |
52 Week Range | 6.300 - 13.50 |
Volume | 291,658 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 90,745 |
Chart
About Nyxoah SA - Ordinary Shares (NYXH)
Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative therapeutic solutions for the treatment of obstructive sleep apnea (OSA). Their primary product features a novel implantable neurostimulator designed to improve airway muscle function during sleep, thereby reducing the frequency of breathing disruptions caused by OSA. Nyxoah's approach offers a minimally invasive alternative to traditional continuous positive airway pressure (CPAP) therapy, aimed at enhancing patient comfort and compliance. The company is dedicated to advancing the understanding and treatment of sleep disorders, striving to improve the quality of life for patients worldwide. Read More
News & Press Releases
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 3, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 26, 2025
By Nyxoah · Via GlobeNewswire · March 26, 2025
REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · March 13, 2025

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
By Nyxoah · Via GlobeNewswire · March 10, 2025

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
By Nyxoah · Via GlobeNewswire · March 3, 2025

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates
By Nyxoah · Via GlobeNewswire · February 19, 2025

By Nyxoah · Via GlobeNewswire · December 20, 2024

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London
By Nyxoah · Via GlobeNewswire · December 13, 2024

REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · November 27, 2024

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
By Nyxoah · Via GlobeNewswire · November 20, 2024

REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET
By Nyxoah · Via GlobeNewswire · November 19, 2024

By Nyxoah · Via GlobeNewswire · November 18, 2024

REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · November 6, 2024

Nyxoah Appoints John Landry as Chief Financial Officer
By Nyxoah · Via GlobeNewswire · November 4, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
By Nyxoah · Via GlobeNewswire · October 22, 2024

Via Benzinga · October 11, 2024

REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · October 9, 2024

INSIDE INFORMATIONREGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · October 7, 2024